Do analysts rate SAFX or BLGO?

XCF Global Capital presently has a consensus price target of $0.70, suggesting a potential upside of 66.31%. Given XCF Global Capital's stronger consensus rating and higher probable upside, equities analysts plainly believe XCF Global Capital is more favorable than BioLargo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XCF Global Capital 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer AMTX or BLGO?

Aemetis currently has a consensus price target of $11.88, indicating a potential upside of 619.70%. Given Aemetis' stronger consensus rating and higher probable upside, analysts plainly believe Aemetis is more favorable than BioLargo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aemetis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is AMTX or BLGO more profitable?

BioLargo has a net margin of -11.45% compared to Aemetis' net margin of -35.43%. Aemetis' return on equity of 0.00% beat BioLargo's return on equity. Company Net Margins Return on Equity Return on Assets Aemetis -35.43% N/A -33.44% BioLargo -11.45% -39.90% -22.06%

Do analysts rate CBUS or BLGO?

Cibus currently has a consensus price target of $9.00, indicating a potential upside of 547.48%. Given Cibus' stronger consensus rating and higher possible upside, equities analysts plainly believe Cibus is more favorable than BioLargo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cibus 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, CBUS or BLGO?

BioLargo has higher revenue and earnings than Cibus. BioLargo is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cibus $4.29M 24.76 -$127.08M -$1.97 N/A BioLargo $12.23M 2.91 -$3.50M -$0.04 N/A

Is CBUS or BLGO more profitable?

BioLargo has a net margin of -11.45% compared to Cibus' net margin of -2,366.33%. BioLargo's return on equity of -39.90% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Cibus -2,366.33% -200.87% -28.28% BioLargo -11.45% -39.90% -22.06%

Do analysts prefer ARQ or BLGO?

ARQ currently has a consensus price target of $7.50, indicating a potential upside of 230.40%. Given ARQ's stronger consensus rating and higher possible upside, equities analysts plainly believe ARQ is more favorable than BioLargo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARQ 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, ARQ or BLGO?

BioLargo has lower revenue, but higher earnings than ARQ. BioLargo is trading at a lower price-to-earnings ratio than ARQ, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ARQ $120.34M 0.81 -$52.61M -$1.29 N/A BioLargo $12.23M 2.91 -$3.50M -$0.04 N/A

Is ARQ or BLGO more profitable?

BioLargo has a net margin of -11.45% compared to ARQ's net margin of -43.93%. ARQ's return on equity of -2.67% beat BioLargo's return on equity. Company Net Margins Return on Equity Return on Assets ARQ -43.93% -2.67% -2.00% BioLargo -11.45% -39.90% -22.06%

Do analysts prefer FSI or BLGO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flexible Solutions International 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

BioLargo (BLGO) Competitors

$0.11 0.00 (0.00%)

As of 07/2/2026 03:45 PM Eastern

Compare

BLGO vs. SAFX, AMTX, CBUS, ARQ, and FSI

Should you buy BioLargo stock or one of its competitors? MarketBeat compares BioLargo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioLargo include XCF Global Capital (SAFX), Aemetis (AMTX), Cibus (CBUS), ARQ (ARQ), and Flexible Solutions International (FSI). These companies are all part of the "chemicals" industry.

How does BioLargo compare to XCF Global Capital?

XCF Global Capital (NASDAQ:SAFX) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

XCF Global Capital presently has a consensus price target of $0.70, suggesting a potential upside of 66.31%. Given XCF Global Capital's stronger consensus rating and higher probable upside, equities analysts plainly believe XCF Global Capital is more favorable than BioLargo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XCF Global Capital	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

XCF Global Capital has a net margin of 300.85% compared to BioLargo's net margin of -11.45%. BioLargo's return on equity of -39.90% beat XCF Global Capital's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XCF Global Capital	300.85%	-588.22%	-29.08%
BioLargo	-11.45%	-39.90%	-22.06%

In the previous week, XCF Global Capital's average media sentiment score of 0.00 equaled BioLargo'saverage media sentiment score.

Company	Overall Sentiment
XCF Global Capital	Neutral
BioLargo	Neutral

XCF Global Capital has higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than XCF Global Capital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XCF Global Capital	$20.82M	6.72	$74.02M	-$0.68	N/A
BioLargo	$12.23M	2.91	-$3.50M	-$0.04	N/A

52.3% of XCF Global Capital shares are held by institutional investors. Comparatively, 0.0% of BioLargo shares are held by institutional investors. 0.1% of XCF Global Capital shares are held by insiders. Comparatively, 19.3% of BioLargo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

XCF Global Capital has a beta of -0.32, suggesting that its stock price is 132% less volatile than the broader market. Comparatively, BioLargo has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

Summary

XCF Global Capital beats BioLargo on 9 of the 14 factors compared between the two stocks.

How does BioLargo compare to Aemetis?

Aemetis (NASDAQ:AMTX) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

BioLargo has lower revenue, but higher earnings than Aemetis. BioLargo is trading at a lower price-to-earnings ratio than Aemetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aemetis	$219.71M	0.53	-$77M	-$1.19	N/A
BioLargo	$12.23M	2.91	-$3.50M	-$0.04	N/A

Aemetis has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, BioLargo has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

27.0% of Aemetis shares are held by institutional investors. Comparatively, 0.0% of BioLargo shares are held by institutional investors. 13.0% of Aemetis shares are held by company insiders. Comparatively, 19.3% of BioLargo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aemetis currently has a consensus price target of $11.88, indicating a potential upside of 619.70%. Given Aemetis' stronger consensus rating and higher probable upside, analysts plainly believe Aemetis is more favorable than BioLargo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aemetis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aemetis' average media sentiment score of 0.00 equaled BioLargo'saverage media sentiment score.

Company	Overall Sentiment
Aemetis	Neutral
BioLargo	Neutral

BioLargo has a net margin of -11.45% compared to Aemetis' net margin of -35.43%. Aemetis' return on equity of 0.00% beat BioLargo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aemetis	-35.43%	N/A	-33.44%
BioLargo	-11.45%	-39.90%	-22.06%

Summary

Aemetis beats BioLargo on 8 of the 14 factors compared between the two stocks.

How does BioLargo compare to Cibus?

Cibus (NASDAQ:CBUS) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Cibus had 1 more articles in the media than BioLargo. MarketBeat recorded 1 mentions for Cibus and 0 mentions for BioLargo. Cibus' average media sentiment score of 0.00 equaled BioLargo'saverage media sentiment score.

Company	Overall Sentiment
Cibus	Neutral
BioLargo	Neutral

BioLargo has higher revenue and earnings than Cibus. BioLargo is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$4.29M	24.76	-$127.08M	-$1.97	N/A
BioLargo	$12.23M	2.91	-$3.50M	-$0.04	N/A

BioLargo has a net margin of -11.45% compared to Cibus' net margin of -2,366.33%. BioLargo's return on equity of -39.90% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,366.33%	-200.87%	-28.28%
BioLargo	-11.45%	-39.90%	-22.06%

Cibus currently has a consensus price target of $9.00, indicating a potential upside of 547.48%. Given Cibus' stronger consensus rating and higher possible upside, equities analysts plainly believe Cibus is more favorable than BioLargo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cibus has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, BioLargo has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

33.8% of Cibus shares are held by institutional investors. Comparatively, 0.0% of BioLargo shares are held by institutional investors. 31.2% of Cibus shares are held by insiders. Comparatively, 19.3% of BioLargo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Cibus beats BioLargo on 9 of the 15 factors compared between the two stocks.

How does BioLargo compare to ARQ?

ARQ (NASDAQ:ARQ) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

BioLargo has lower revenue, but higher earnings than ARQ. BioLargo is trading at a lower price-to-earnings ratio than ARQ, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARQ	$120.34M	0.81	-$52.61M	-$1.29	N/A
BioLargo	$12.23M	2.91	-$3.50M	-$0.04	N/A

ARQ currently has a consensus price target of $7.50, indicating a potential upside of 230.40%. Given ARQ's stronger consensus rating and higher possible upside, equities analysts plainly believe ARQ is more favorable than BioLargo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARQ	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ARQ has a beta of 2, meaning that its share price is 100% more volatile than the broader market. Comparatively, BioLargo has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

18.5% of ARQ shares are held by institutional investors. Comparatively, 0.0% of BioLargo shares are held by institutional investors. 20.1% of ARQ shares are held by company insiders. Comparatively, 19.3% of BioLargo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ARQ's average media sentiment score of 0.00 equaled BioLargo'saverage media sentiment score.

Company	Overall Sentiment
ARQ	Neutral
BioLargo	Neutral

BioLargo has a net margin of -11.45% compared to ARQ's net margin of -43.93%. ARQ's return on equity of -2.67% beat BioLargo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARQ	-43.93%	-2.67%	-2.00%
BioLargo	-11.45%	-39.90%	-22.06%

Summary

ARQ beats BioLargo on 10 of the 14 factors compared between the two stocks.

How does BioLargo compare to Flexible Solutions International?

Flexible Solutions International (NYSE:FSI) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Flexible Solutions International has a net margin of 10.80% compared to BioLargo's net margin of -11.45%. Flexible Solutions International's return on equity of 10.61% beat BioLargo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flexible Solutions International	10.80%	10.61%	7.32%
BioLargo	-11.45%	-39.90%	-22.06%

Flexible Solutions International has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, BioLargo has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

In the previous week, Flexible Solutions International had 2 more articles in the media than BioLargo. MarketBeat recorded 2 mentions for Flexible Solutions International and 0 mentions for BioLargo. Flexible Solutions International's average media sentiment score of 1.00 beat BioLargo's score of 0.00 indicating that Flexible Solutions International is being referred to more favorably in the media.

Company	Overall Sentiment
Flexible Solutions International	Positive
BioLargo	Neutral

Flexible Solutions International has higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than Flexible Solutions International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flexible Solutions International	$39.34M	2.02	$2.78M	$0.06	104.17
BioLargo	$12.23M	2.91	-$3.50M	-$0.04	N/A

54.3% of Flexible Solutions International shares are owned by institutional investors. Comparatively, 0.0% of BioLargo shares are owned by institutional investors. 35.8% of Flexible Solutions International shares are owned by company insiders. Comparatively, 19.3% of BioLargo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flexible Solutions International	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	3.00
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Flexible Solutions International beats BioLargo on 14 of the 15 factors compared between the two stocks.

Get BioLargo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLGO vs. The Competition

Export

Metric	BioLargo	Chemicals & allied products Industry	Construction Sector	NASDAQ Exchange
Market Cap	$35.57M	$7.93B	$9.83B	$12.48B
Dividend Yield	N/A	1.09%	1.94%	6.52%
P/E Ratio	-11.05	N/A	20.11	24.70
Price / Sales	2.91	2.54	28.08	99.46
Price / Cash	N/A	270.17	17.39	57.09
Price / Book	11.05	6.96	5.53	6.46
Net Income	-$3.50M	$659.84M	$560.79M	$337.01M
7 Day Performance	-2.21%	-0.77%	-2.37%	1.69%
1 Month Performance	-7.92%	-2.57%	22.33%	3.81%
1 Year Performance	-44.47%	-13.93%	8.14%	23.90%

BioLargo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLGO BioLargo	N/A	$0.11 flat	N/A	-44.5%	$35.57M	$12.23M	N/A	30	Gap Up
SAFX XCF Global Capital	2.687 of 5 stars	$0.42 -3.1%	$0.70 +66.3%	N/A	$139.98M	$20.82M	N/A	N/A	Gap Up
AMTX Aemetis	1.6362 of 5 stars	$1.65 +3.8%	$11.88 +619.7%	-46.9%	$116.10M	$219.71M	N/A	160
CBUS Cibus	1.2452 of 5 stars	$1.39 -2.1%	$9.00 +547.5%	-12.5%	$106.10M	$4.29M	N/A	48	Gap Up
ARQ ARQ	3.4227 of 5 stars	$2.27 -3.4%	$7.50 +230.4%	-61.3%	$97.45M	$120.34M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLGO) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLargo (BLGO) Competitors

BLGO vs. SAFX, AMTX, CBUS, ARQ, and FSI

How does BioLargo compare to XCF Global Capital?

Summary

How does BioLargo compare to Aemetis?

Summary

How does BioLargo compare to Cibus?

Summary

How does BioLargo compare to ARQ?

Summary

How does BioLargo compare to Flexible Solutions International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLGO vs. The Competition

BioLargo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLargo (BLGO) Competitors

BLGO vs. SAFX, AMTX, CBUS, ARQ, and FSI

How does BioLargo compare to XCF Global Capital?

Do analysts rate SAFX or BLGO?

Is SAFX or BLGO more profitable?

Does the media favor SAFX or BLGO?

Which has better valuation and earnings, SAFX or BLGO?

Do insiders and institutionals have more ownership in SAFX or BLGO?

Which has more volatility and risk, SAFX or BLGO?

Summary

How does BioLargo compare to Aemetis?

Which has better earnings & valuation, AMTX or BLGO?

Which has more volatility and risk, AMTX or BLGO?

Do institutionals and insiders hold more shares of AMTX or BLGO?

Do analysts prefer AMTX or BLGO?

Does the media favor AMTX or BLGO?

Is AMTX or BLGO more profitable?

Summary

How does BioLargo compare to Cibus?

Does the media prefer CBUS or BLGO?

Which has stronger valuation & earnings, CBUS or BLGO?

Is CBUS or BLGO more profitable?

Do analysts rate CBUS or BLGO?

Which has more risk & volatility, CBUS or BLGO?

Do institutionals & insiders believe in CBUS or BLGO?

Summary

How does BioLargo compare to ARQ?

Which has stronger earnings & valuation, ARQ or BLGO?

Do analysts prefer ARQ or BLGO?

Which has more risk & volatility, ARQ or BLGO?

Do institutionals and insiders believe in ARQ or BLGO?

Does the media prefer ARQ or BLGO?

Is ARQ or BLGO more profitable?

Summary

How does BioLargo compare to Flexible Solutions International?

Is FSI or BLGO more profitable?

Which has more volatility & risk, FSI or BLGO?

Does the media refer more to FSI or BLGO?

Which has higher valuation and earnings, FSI or BLGO?

Do institutionals and insiders have more ownership in FSI or BLGO?

Do analysts prefer FSI or BLGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLGO vs. The Competition

BioLargo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools